Status:
COMPLETED
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Lead Sponsor:
Pfizer
Conditions:
Carcinoma
Renal Cell
Eligibility:
All Genders
18+ years
Brief Summary
Research Questions: To understand the clinical outcomes of patients treated with sunitinib in first line and axitinib in second line in a real world setting as therapies for metastatic and/or advance...
Detailed Description
Research Questions: To understand the clinical outcomes of patients treated with sunitinib in first line and axitinib in second line in a real world setting as therapies for metastatic and/or advance...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Over the age of 18 years
- Diagnosis of renal cell carcinoma
- Treatment with sunitinib and/or axitinib
- Timeframe: from database inception date (2002) until June 30, 2018.
- Exclusion criteria
- Patients meeting any of the following criteria will not be included in the study:
- Under the age of 18 years
- Diagnosis other than renal cell carcinoma
- No treatment with sunitinib and/or axitinib
Exclusion
Key Trial Info
Start Date :
September 27 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 18 2020
Estimated Enrollment :
684 Patients enrolled
Trial Details
Trial ID
NCT04033991
Start Date
September 27 2019
End Date
December 18 2020
Last Update
April 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer UK
London, United Kingdom